NM-702
Grundinformationen
- CAS
139145-84-9- Standard-SMILES
Cl.O=c1[nH]nc(OCCCc2ccc(Cl)cc2)c(NCc2cccnc2)c1Br- InChIKey
QWGUGDYWUADMGB-UHFFFAOYSA-N- Summenformel
- C19H19BrCl2N4O2
- Durchschnittliche Molmasse
- 486,2 g/mol
- Monoisotopische Masse
- 484,00684
Überblick
Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans. M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and asthma. In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed. Intermittent claudication is a major symptom of arteriosclerosis obliterans. It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries. It is estimated that about 6 million people suffer from intermittent claudication in the USA, with only 10 percent of these people currently receiving treatment. Patients with claudication experience significant disability, owing to their exercise limitation. Therapeutic options to improve exercise performance in these patients are limited
Namen und Bezeichner
- Bevorzugter Name
- NM-702
- IUPAC
- 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1H-pyridazin-6-one;hydrochloride
Namen und Synonyme
NM-702RefChem:858687Parogrelil hydrochloride878796-94-265O9DMS368UNII-65O9DMS368139145-84-93(2H)-Pyridazinone, 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-((3-pyridinylmethyl)amino)-, hydrochloride (1:1)5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1H-pyridazin-6-one;hydrochlorideNM702Parogrelil (hydrochloride)orb1699721
Weitere Namen anzeigen
SCHEMBL1739368QWGUGDYWUADMGB-UHFFFAOYSA-NDTXSID701007830AKOS0407491174-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochlorideCS-0034672T282964-Bromo-6-[3-(4-chlorophenyl)propoxy]-5-{[(pyridin-3-yl)methyl]amino}pyridazin-3-ol--hydrogen chloride (1/1)
Datenbank-Bezeichner
- CAS
139145-84-9、878796-94-2- PubChem CID
- 9848253
- DTXSID
DTXSID701007830- UNII
- 65O9DMS368
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 75,6 Ų
- H-Brücken-Donoren
- 3
- H-Brücken-Akzeptoren
- 5
- Frei drehbare Bindungen
- 8
- Schwere Atome
- 28
- Formalladung
- 0
- Komplexität
- 576
Chemie und Industrie
Pharmakologische Informationen
Pharmacodynamics
Intermittent claudication is a major symptom of arteriosclerosis obliterans. It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries. Patients with claudication experience significant disability, owing to their exercise limitation. Therapeutic options to improve exercise performance in these patients are limited. NM-702 is a novel drug that inhibits phosphodiesterase as well as thromboxane A2 synthase.
Mechanism of ActionNM-702 is a novel drug that inhibits phosphodiesterase as well as thromboxane A2 synthase.
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…